Therefore, the CXCL8/CXCR2 axis antagonists have been evaluated in clinical trials of various respiratory distress conditions in influenza, eczema, and chronic obstructive pulmonary disease (COPD). The gene discussed is CXCR2; the disease is chronic obstructive pulmonary disease.